A study by New York University researchers, published this week in the journal Proceedings of the National Academy of Sciences, explains why cancers not only stop responding to kinase inhibitors but come back stronger, a finding that could inform which drugs oncologists use as a first-line treatment.
Researchers at NYU Dentistry’s Pain Research Center have been awarded a five-year, $8 million NIH grant to study signaling mechanisms that generate oral cancer pain. The funding is part of the NIH’s Helping to End Addiction Long-term Initiative, which supports the development of safe and effective therapeutics to treat pain in an effort to end the opioid crisis.
